1 / 14

Gianpietro Dotti G Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX

Clinical Experience at Baylor College of Medicine with T Lymphocytes Genetically Modified Using Retroviral Vectors. Gianpietro Dotti G Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX . Type of vector and packaging cell lines. Moloney-derived retroviral vector

adamdaniel
Télécharger la présentation

Gianpietro Dotti G Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Experience at Baylor College of Medicine with T Lymphocytes Genetically Modified Using Retroviral Vectors Gianpietro Dotti G Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX

  2. Type of vector and packaging cell lines • Moloney-derived retroviral vector • (SFG from Mulligan R.) • Packaging cell line Phoenix-Eco • original cells from ATCC • generation of a master cell bank under GMP conditions • Packaging cell line PG13 • original cells from ATCC • generation of a master cell bank under GMP conditions

  3. Generation of stable packaging cell line • Multiple infection of PG13 cells using Eco-pseudotyped retroviral particles (transient supernatant) • Generation of single cell clone from infected PG13 cells • Expansion of the single cell clone to make a master cell bank (MCB) • Production and collection of supernatant from the MCB

  4. Manufacturing • Manufacturing of the single cell clone under GLP conditions • Expansion of the master cell bank (MCB) and production of the retroviral supernatant under GMP conditions

  5. Packaging cell lines • 9 Packaging cell lines generated and tested • RCR detection negative in all cases for both Ecotropic and Galv envelopes (co-culture assay) • 18 lots of supernatant produced and tested • RCR detection negative in all cases for GalV envelope (co-culture assay)

  6. Clinical protocols IND Transgene Cell product Disease #11217 CAR.GD2z Activated T cells vs Neuroblastoma EBV-CTLs 19 patients treated. 38 T-cell/CTL products infused all negative by co-culture assay.

  7. Clinical protocols IND Transgene Cell product Disease #13296 CAR.CD19.CD28z vsActivated T cells CD19+ Lymphoma CAR.CD19z #13902 CAR.CD19.CD28z vs Activated T cells vs CD19+ Lymphoma CAR.CD19z EBV-CTLs #13958 CAR.CD19.28z Virus-specific CTLs CD19+ Lymphoma 8 patients treated (6 in # and 2 in #). 16 T-cell/CTL products infused. 6 negative by co-culture assay. 8 pending and 2 not needed (frozen within 4 days of culture).

  8. Clinical protocols IND Transgene Cell product Disease #14050 CAR.HER2.CD28z Activated T cells Osteosarcoma #14036 CAR.HER2.CD28z and EBV-CTLs Lung cancer TGFbRIIdcyt (DNRII) #14050 CAR.HER2.CD28.z CMV-specific CTLs Glioblastoma 4 patients treated (2 in #14050 and 2 in #14036). 4 T-cell/CTL products infused. 1 negative by co-culture assay. 3 pending.

  9. Clinical protocols IND Transgene Cell product Disease #12830 TGFbRIIdcyt (DNRII) LMP-2a-CTLs EBV+ Lymphoma 4 patients treated. 4 CTL products infused. All negative by co-culture assay.

  10. Clinical protocols IND Transgene Cell product Disease # 13813 icaapase9.2A.DCD19 allodepleted T cells hematological malignancies/haplo HSC transplant 4 patients treated. 4 T-cell products infused. All negative by co-culture assay.

  11. T/CTL line infused summary 92 lines infused to 73 patients 2 did not require assay 8 results pending 82 lines negative RCR co-culture assay for GalV envelope

  12. Follow up patient samples - 73 patients infused (follow up from 1 month to 15 years) - 371 samples analyzed - All RCR negative by Q-PCR (GalV envelope)

  13. Previous experience at St. Jude Children’s Research Hospital (Gene marking) • 34 patients infused with gene marked EBV-specific CTLs • All 34 CTL lines negative by co-culture assay • - 271 follow up samples all negative by PCR assay (samples continue to be archived from 2002 but no longer tested)

  14. Conclusions and Suggestions • T cell/CTLs modified with retroviral vectors are consistently RCR negative • RCR assay based on co-culture is time consuming and extremely expensive limiting the possibility to extend the use of promising immunotherapy approaches • Based on the current experience samples can be stored and analyzed for RCR contamination in case of severe adverse events

More Related